Lee Ruth Z, Veale Douglas J
Department of Rheumatology, St Vincent's University Hospital, Elm Park, Dublin, Ireland.
Drugs. 2002;62(16):2349-59. doi: 10.2165/00003495-200262160-00003.
Spondyloarthropathies (SpA) are a group of inflammatory arthritides classified according to common features of peripheral and spinal arthritis. The conventional anti-inflammatory and disease-modifying or slow-acting anti-rheumatic drugs do appear to be efficacious in treatment of the peripheral arthritis in a comparable fashion to seropositive rheumatoid arthritis, however, their efficacy in axial disease is unproven. This review examines new pharmacological developments in the treatment of SpA including the specific features of sacroiliitis, enthesitis and spondylitis in addition to the peripheral manifestations. The main points that are discussed are new cyclo-oxygenase (COX)-2 specific anti-inflammatories, biological therapies, such as anti-TNF compounds, and novel uses of well-known agents.
脊柱关节炎（SpA）是一组根据外周和脊柱关节炎的共同特征分类的炎性关节炎。传统的抗炎药和改善病情或慢作用抗风湿药在治疗外周关节炎方面似乎确实有效，其效果与血清阳性类风湿关节炎相当，然而，它们在轴性疾病中的疗效尚未得到证实。本综述探讨了脊柱关节炎治疗中的新药理学进展，包括骶髂关节炎、附着点炎和脊柱炎的具体特征以及外周表现。讨论的要点包括新型环氧化酶（COX）-2特异性抗炎药、生物疗法（如抗TNF化合物）以及知名药物的新用途。
